Literature DB >> 17038527

The hypomorphic Gata1low mutation alters the proliferation/differentiation potential of the common megakaryocytic-erythroid progenitor.

Barbara Ghinassi1, Massimo Sanchez, Fabrizio Martelli, Giovanni Amabile, Alessandro Maria Vannucchi, Giovanni Migliaccio, Stuart H Orkin, Anna Rita Migliaccio.   

Abstract

Recent evidence suggests that mutations in the Gata1 gene may alter the proliferation/differentiation potential of hemopoietic progenitors. By single-cell cloning and sequential replating experiments of prospectively isolated progenitor cells, we demonstrate here that the hypomorphic Gata1low mutation increases the proliferation potential of a unique class of progenitor cells, similar in phenotype to adult common erythroid/megakaryocytic progenitors (MEPs), but with the "unique" capacity to generate erythroblasts, megakaryocytes, and mast cells in vitro. Conversely, progenitor cells phenotypically similar to mast cell progenitors (MCPs) are not detectable in the marrow from these mutants. At the single-cell level, about 11% of Gata1low progenitor cells, including MEPs, generate cells that will continue to proliferate in cultures for up to 4 months. In agreement with these results, trilineage (erythroid, megakaryocytic, and mastocytic) cell lines are consistently isolated from bone marrow and spleen cells of Gata1low mice. These results confirm the crucial role played by Gata1 in hematopoietic commitment and identify, as a new target for the Gata1 action, the restriction point at which common myeloid progenitors become either MEPs or MCPs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17038527      PMCID: PMC1794062          DOI: 10.1182/blood-2006-07-030726

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  59 in total

1.  The GATA1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down syndrome.

Authors:  Hideo Harigae; Gang Xu; Tomohiro Sugawara; Izumi Ishikawa; Tsutomu Toki; Etsuro Ito
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

2.  GATA-1 converts lymphoid and myelomonocytic progenitors into the megakaryocyte/erythrocyte lineages.

Authors:  Hiromi Iwasaki; Shin-ichi Mizuno; Richard A Wells; Alan B Cantor; Sumiko Watanabe; Koichi Akashi
Journal:  Immunity       Date:  2003-09       Impact factor: 31.745

3.  Single-cell origin of mouse hemopoietic colonies expressing multiple lineages in variable combinations.

Authors:  T Suda; J Suda; M Ogawa
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

4.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.

Authors:  Joshua Wechsler; Marianne Greene; Michael A McDevitt; John Anastasi; Judith E Karp; Michelle M Le Beau; John D Crispino
Journal:  Nat Genet       Date:  2002-08-12       Impact factor: 38.330

5.  Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines.

Authors:  J S Greenberger; M A Sakakeeny; R K Humphries; C J Eaves; R J Eckner
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

6.  Natural history of GATA1 mutations in Down syndrome.

Authors:  Momin Ahmed; Alexander Sternberg; Georgina Hall; Angela Thomas; Owen Smith; Aengus O'Marcaigh; Robert Wynn; Richard Stevens; Michael Addison; Derek King; Barbara Stewart; Brenda Gibson; Irene Roberts; Paresh Vyas
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

7.  Cloning of cDNA for the major DNA-binding protein of the erythroid lineage through expression in mammalian cells.

Authors:  S F Tsai; D I Martin; L I Zon; A D D'Andrea; G G Wong; S H Orkin
Journal:  Nature       Date:  1989-06-08       Impact factor: 49.962

8.  Characterization of mouse clonogenic megakaryocyte progenitors.

Authors:  Thanyaphong Na Nakorn; Toshihiro Miyamoto; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-18       Impact factor: 11.205

9.  Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome.

Authors:  Gang Xu; Masumi Nagano; Rika Kanezaki; Tsutomu Toki; Yasuhide Hayashi; Takeshi Taketani; Tomohiko Taki; Tetsuo Mitui; Kenichi Koike; Koji Kato; Masue Imaizumi; Isao Sekine; Yasuhiko Ikeda; Ryoji Hanada; Masahiro Sako; Kazuko Kudo; Seiji Kojima; Osamu Ohneda; Masayuki Yamamoto; Etsuro Ito
Journal:  Blood       Date:  2003-06-19       Impact factor: 22.113

10.  Selection of lineage-restricted cell lines immortalized at different stages of hematopoietic differentiation from the murine cell line 32D.

Authors:  G Migliaccio; A R Migliaccio; B L Kreider; G Rovera; J W Adamson
Journal:  J Cell Biol       Date:  1989-08       Impact factor: 10.539

View more
  24 in total

1.  CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin.

Authors:  Maria Verrucci; Alessandro Pancrazzi; Miguel Aracil; Fabrizio Martelli; Paola Guglielmelli; Maria Zingariello; Barbara Ghinassi; Emanuela D'Amore; José Jimeno; Alessandro M Vannucchi; Anna Rita Migliaccio
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

2.  Clonogenic mast cell progenitors and their excess numbers in chimeric BALB/c mice with inactivated GATA-1.

Authors:  Donald Metcalf; Ian Majewski; Sandra Mifsud; Ladina Di Rago; Warren S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-13       Impact factor: 11.205

Review 3.  Models of haematopoiesis: seeing the wood for the trees.

Authors:  Rhodri Ceredig; Antonius G Rolink; Geoffrey Brown
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

Review 4.  Mast cell transcriptional networks.

Authors:  Clifford M Takemoto; Youl-Nam Lee; Anil G Jegga; Daniella Zablocki; Stephanie Brandal; Amir Shahlaee; Suming Huang; Ying Ye; Sivakumar Gowrisankar; Jimmy Huynh; Michael A McDevitt
Journal:  Blood Cells Mol Dis       Date:  2008-04-14       Impact factor: 3.039

Review 5.  GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy.

Authors:  Te Ling; John D Crispino; Maria Zingariello; Fabrizio Martelli; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2018-02-19       Impact factor: 2.929

6.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

7.  Gata1 expression driven by the alternative HS2 enhancer in the spleen rescues the hematopoietic failure induced by the hypomorphic Gata1low mutation.

Authors:  Anna Rita Migliaccio; Fabrizio Martelli; Maria Verrucci; Massimo Sanchez; Mauro Valeri; Giovanni Migliaccio; Alessandro Maria Vannucchi; Maria Zingariello; Angela Di Baldassarre; Barbara Ghinassi; Rosa Alba Rana; Yvette van Hensbergen; Willem E Fibbe
Journal:  Blood       Date:  2009-07-01       Impact factor: 22.113

8.  Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosis.

Authors:  Eva Zetterberg; Maria Verrucci; Fabrizio Martelli; Maria Zingariello; Laura Sancillo; Emanuela D'Amore; Rosa Alba Rana; Anna Rita Migliaccio
Journal:  Platelets       Date:  2013-10-31       Impact factor: 3.862

9.  Trisomy 21 enhances human fetal erythro-megakaryocytic development.

Authors:  Stella T Chou; Joanna B Opalinska; Yu Yao; Myriam A Fernandes; Anna Kalota; John S J Brooks; John K Choi; Alan M Gewirtz; Gwenn-ael Danet-Desnoyers; Richard L Nemiroff; Mitchell J Weiss
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

10.  Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease.

Authors:  Anna Rita Migliaccio; Fabrizio Martelli; Maria Verrucci; Giovanni Migliaccio; Alessandro Maria Vannucchi; Hongyu Ni; Mingjiang Xu; Yi Jiang; Betty Nakamoto; Thalia Papayannopoulou; Ronald Hoffman
Journal:  Exp Hematol       Date:  2008-02       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.